BACKGROUND Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention
D ual-antiplatelet therapy (DAPT) with
aspirin and an inhibitor of the platelet P2Y 12 receptor is necessary to prevent early and largely stent-related thrombotic complications after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) (1) . Although continuation of DAPT confers substantial and durable benefits that extend beyond the local stented segment, bleeding risk also increases with continued exposure to antiplatelet therapy. As a result and in the absence of any mortality advantage with a prolonged DAPT strategy, clinical decision making surrounding the optimal duration of DAPT must be predicated on balancing long-term risks for both coronary thrombosis and major bleeding (MB) (2) .
To date, most ischemic and bleeding risk algorithms after PCI have focused on in-hospital events or short-term risk (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Although these scales are use- JACC VOL. 67, NO. 19, 2016 Baber et al.
Thrombotic and Bleeding Events After DES women (17) . Creatinine clearance (CrCl) was calculated using the Cockcroft-Gault formula (18) . (19) . In the first step, we generated 10 imputations from the original dataset, using multivariate normal regression to substitute missing values for hemoglobin and serum creatinine within each impute. In the second step, separate models, 1 for each dependent outcome, were fit to each replicate using backward selection with an entry criterion of Baber et al. PCI, and prior MI. In the third step, separate fully fitted models were generated using those covariates selected as independent predictors in at least 1 impute with regression coefficients combined across all imputed datasets as described by Rubin (20) .
Variables remaining significant at a threshold p value of <0.05 were retained as final predictors. Model performance was assessed using metrics of discrimination (Harrel's C statistic) and calibration Baber et al. No 0
Abbreviations as in Table 1 . 
Diabetes mellitus
None 0
Non-insulin-dependent þ1
Insulin-dependent þ3
Acute coronary syndrome
No 0
Yes, Tn-negative þ1
Yes, Tn-positive þ2
Current smoking Yes þ1
CrCl <60 ml/min Present þ2
Absent 0
Prior PCI
Yes þ2
Prior CABG
Tn ¼ troponin; other abbreviations as in Table 1 . 
DAPT (n ¼
18
PREDICTORS OF CTE AND MB AND INTEGER RISK
SCORES. Point estimates and corresponding 95% confidence intervals for each covariate in the final prediction models are shown in Table 3 .
The strongest 3 predictors for CTEs, quantified and ranked using the value of the t statistic, were insulin-dependent diabetes mellitus, CrCl <60 ml/min, and prior PCI. Analogously, the strongest contributors for MB were anemia, CrCl <60 ml/min, and current smoking. For the CTE model, discrimi- Table 1 ). As in the original PARIS report, this time-dependent covariate allowed a patient to contribute exposure time to the various DAPT cessation modes (discontinuation, interruption, and disruption).
Using the fully adjusted regression coefficients from the final Cox models, we developed integerbased risk scores for both outcomes, shown in Tables 4 and 5 , respectively. For CTEs, the scores ranged from 0 to 10, and patients were grouped according to low (0 to 2), intermediate (3 or 4) , and high ($5) thrombotic risk. The overall distribution of thrombotic risk scores and corresponding predicted CTE rates are displayed in Figure 2A . Analogously, the range of integer scores for MB was 0 to 14, with patients categorized at low (0 to 3), intermediate (4 to 7) and high ($8) bleeding risk. The distribution of bleeding risk scores and predicted estimates for MB are displayed in Figure 2B . As shown in Figure 3 Thrombotic and major bleeding risk bar graphs display cross-classification of the entire cohort with thrombotic and major bleeding risk scores.
Baber et al. The x-axis displays bleeding risk score. The y-axis displays absolute risk difference in coronary thrombosis and major bleeding at 2 years using the adjusted probability estimates from each respective outcome model. Positive risk differences indicate that a patient's risk for thrombosis exceeds bleeding whereas negative risk differences indicate the opposite. Each line is fitted to the mean risk difference according to bleeding risk score and ischemic risk category (low, intermediate, or high). Shaded areas represent 95% confidence intervals for mean risk difference.
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